These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

641 related items for PubMed ID: 19953708

  • 41. (18)F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer.
    Jingu K, Kaneta T, Nemoto K, Takeda K, Ogawa Y, Ariga H, Koto M, Sakayauchi T, Takai Y, Takahashi S, Yamada S.
    Int J Clin Oncol; 2010 Apr; 15(2):184-90. PubMed ID: 20217449
    [Abstract] [Full Text] [Related]

  • 42. Prediction of Response to Neoadjuvant Chemotherapy and Radiation Therapy with Baseline and Restaging 18F-FDG PET Imaging Biomarkers in Patients with Esophageal Cancer.
    Beukinga RJ, Hulshoff JB, Mul VEM, Noordzij W, Kats-Ugurlu G, Slart RHJA, Plukker JTM.
    Radiology; 2018 Jun; 287(3):983-992. PubMed ID: 29533721
    [Abstract] [Full Text] [Related]

  • 43. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer.
    Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Masuda N, Fukuchi M, Manda R, Tsukada K, Oriuchi N, Endo K.
    Am J Surg; 2002 Sep; 184(3):279-83. PubMed ID: 12354600
    [Abstract] [Full Text] [Related]

  • 44. Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma.
    Hamai Y, Hihara J, Emi M, Furukawa T, Yamakita I, Kurokawa T, Okada M.
    Ann Thorac Surg; 2016 Oct; 102(4):1132-9. PubMed ID: 27319990
    [Abstract] [Full Text] [Related]

  • 45. Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography.
    Lordick F.
    Recent Results Cancer Res; 2012 Oct; 196():201-11. PubMed ID: 23129376
    [Abstract] [Full Text] [Related]

  • 46. Treatment Response to Neoadjuvant Therapy in Squamous Esophageal Cancer-Correlation Between Metabolic Response and Histopathology.
    Kaderi ASA, Sabita J, Tiwari VK, Pawar A, Niyogi D.
    J Gastrointest Cancer; 2024 Jun; 55(2):820-828. PubMed ID: 38308686
    [Abstract] [Full Text] [Related]

  • 47. Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
    Tan S, Kligerman S, Chen W, Lu M, Kim G, Feigenberg S, D'Souza WD, Suntharalingam M, Lu W.
    Int J Radiat Oncol Biol Phys; 2013 Apr 01; 85(5):1375-82. PubMed ID: 23219566
    [Abstract] [Full Text] [Related]

  • 48. Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
    Sakai M, Sohda M, Miyazaki T, Honjo H, Hara K, Ozawa D, Suzuki S, Tanaka N, Yokobori T, Kuwano H.
    Hepatogastroenterology; 2015 Jun 01; 62(140):898-901. PubMed ID: 26902024
    [Abstract] [Full Text] [Related]

  • 49. Prediction of disease-free survival using relative change in FDG-uptake early during neoadjuvant chemoradiotherapy for potentially curable esophageal cancer: A prospective cohort study.
    Hagen PV, Heijl MV, van Berge Henegouwen MI, Boellaard R, Bossuyt PM, Kate FJ, Dekken HV, Hoekstra OS, Sloof GW, Lanschot JJ.
    Dis Esophagus; 2017 Feb 01; 30(2):1-7. PubMed ID: 27001344
    [Abstract] [Full Text] [Related]

  • 50. Predictive Value of Standardized Intratumoral Metabolic Heterogeneity in Locally Advanced Cervical Cancer Treated With Chemoradiation.
    Yang F, Young L, Grigsby P.
    Int J Gynecol Cancer; 2016 May 01; 26(4):777-84. PubMed ID: 27101524
    [Abstract] [Full Text] [Related]

  • 51. Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02).
    Jost C, Binek J, Schuller JC, Bauerfeind P, Metzger U, Werth B, Knuchel J, Frossard JL, Bertschinger P, Brauchli P, Meyenberger C, Ruhstaller T.
    Gastrointest Endosc; 2010 Jun 01; 71(7):1114-21. PubMed ID: 20304399
    [Abstract] [Full Text] [Related]

  • 52. Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy.
    Schmidt M, Bollschweiler E, Dietlein M, Mönig SP, Kobe C, Vallböhmer D, Eschner W, Hölscher A, Schicha H.
    Eur J Nucl Med Mol Imaging; 2009 May 01; 36(5):735-44. PubMed ID: 19096843
    [Abstract] [Full Text] [Related]

  • 53. Prognostic Significance of (18)F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma.
    Yasuda T, Yano M, Miyata H, Yamasaki M, Takiguchi S, Fujiwara Y, Doki Y.
    Ann Surg Oncol; 2015 Aug 01; 22(8):2599-607. PubMed ID: 25524011
    [Abstract] [Full Text] [Related]

  • 54. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy.
    Capirci C, Rampin L, Erba PA, Galeotti F, Crepaldi G, Banti E, Gava M, Fanti S, Mariani G, Muzzio PC, Rubello D.
    Eur J Nucl Med Mol Imaging; 2007 Oct 01; 34(10):1583-93. PubMed ID: 17503039
    [Abstract] [Full Text] [Related]

  • 55. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer.
    Song SY, Kim JH, Ryu JS, Lee GH, Kim SB, Park SI, Song HY, Cho KJ, Ahn SD, Lee SW, Shin SS, Choi EK.
    Int J Radiat Oncol Biol Phys; 2005 Nov 15; 63(4):1053-9. PubMed ID: 15964705
    [Abstract] [Full Text] [Related]

  • 56. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.
    Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS, Lee JY, Lee KH, Kim BT.
    Ann Surg Oncol; 2010 Jan 15; 17(1):115-22. PubMed ID: 19826877
    [Abstract] [Full Text] [Related]

  • 57. Association between prognosis and lymph node status using 18F-fluorodeoxyglucose-positron emission tomography in esophageal squamous cell carcinoma treated with esophagectomy post-neoadjuvant chemotherapy.
    Ohsawa M, Hamai Y, Emi M, Ibuki Y, Kurokawa T, Yoshikawa T, Hirohata R, Kitasaki N, Okada M.
    World J Surg; 2024 Mar 15; 48(3):650-661. PubMed ID: 38686781
    [Abstract] [Full Text] [Related]

  • 58. Relevance of [18F]fluorodeoxyglucose positron emission tomography-positive lymph nodes after neoadjuvant chemotherapy for squamous cell oesophageal cancer.
    Miyata H, Yamasaki M, Takahashi T, Murakami K, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y.
    Br J Surg; 2013 Oct 15; 100(11):1490-7. PubMed ID: 24037571
    [Abstract] [Full Text] [Related]

  • 59. Impact of PET-CT on primary staging and response control on multimodal treatment of esophageal cancer.
    Thurau K, Palmes D, Franzius C, Minin E, Senninger N, Juergens KU, Bruewer M.
    World J Surg; 2011 Mar 15; 35(3):608-16. PubMed ID: 21221582
    [Abstract] [Full Text] [Related]

  • 60. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
    Odawara S, Kitajima K, Katsuura T, Kurahashi Y, Shinohara H, Yamakado K.
    Eur J Radiol; 2018 Apr 15; 101():65-71. PubMed ID: 29571803
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.